公开(公告)号：US20220298220A1

公开(公告)日：2022-09-22

申请号：US17826535

申请日：2022-05-27

Applicant: PINETREE THERAPEUTICS, INC.

Inventor： Yong Sung Kim ,  Ye Jin Kim

IPC: C07K14/705 ,  A61K9/127 ,  A61K47/50 ,  C07K19/00 ,  G01N33/53 ,  G01N33/574 ,  G01N33/68

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

公开(公告)号：US11548915B2

公开(公告)日：2023-01-10

申请号：US16081342

申请日：2017-03-28

Applicant: Pinetree Therapeutics, Inc.

Inventor： Yong Sung Kim ,  Ye Jin Kim

IPC: C07K7/08 ,  C07K16/28 ,  A61K39/395 ,  A61K38/17 ,  A61K38/08 ,  C07K14/71 ,  A61K39/00

Abstract: The present invention relates to methods of overcoming the resistance to an EGFR (Epidermal Growth Factor Receptor)-targeting antibody through a peptide that binds specifically to neuropilin-1 (NRP1). Moreover, the present invention relates to a fusion antibody in which a peptide that binds specifically to NRP1 is fused to an EGFR-targeting antibody, and to a composition of overcoming the resistance to an EGFR-targeting antibody alone by co-administration of the EGFR-targeting antibody and an NRP1-binding peptide-fused Fc. In addition, the fusion antibody according to the present invention, in which the NRP1-specific binding peptide is fused to an EGFR-targeting antibody, overcomes the resistance to the EGFR-targeting antibody alone in pancreatic cancer. Furthermore, the fusion antibody, in which the NRP1-specific binding peptide is fused to the EGFR-targeting antibody, also overcomes resistance to the EGFR-targeting antibody alone even in lung cancer. Thus, the NRP1-specific binding-fused EGFR-targeting antibody according to the present invention may be highly effective in the treatment of various tumors resistant to EGFR-targeting antibody alone.